Want to see KR:011000 full AI Analyst Report?
Top Page
GeneOne Life Science, Inc.
(011000)
Select Model
Select Model
Rating:41Neutral
Price Target:
₩2,550.00
Action:N/A
Date:10/28/26
The score is driven primarily by very weak financial performance (shrinking revenue, negative gross profit, persistent losses, and ongoing cash burn) alongside a deteriorating balance sheet with rising leverage. Technicals also remain weak with the stock below key long-term moving averages and negative MACD; valuation provides limited support due to negative earnings and no indicated dividend yield.
Positive Factors
CDMO Continuity
Securing a long-term Texas lease protects the space needed for VGXI’s CDMO activity and reduces facility uncertainty. Starting a dedicated line at Plant 1 also allows production to begin without waiting for the delayed Conroe facility plan.
Negative Factors
Shrinking Revenue
Multi-year revenue contraction signals weakening commercial scale and makes it harder to absorb fixed operating costs. The sharp 2025 decline is especially concerning because a smaller revenue base reduces the potential for operating leverage and limits resources available for product and business development.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO Continuity
Securing a long-term Texas lease protects the space needed for VGXI’s CDMO activity and reduces facility uncertainty. Starting a dedicated line at Plant 1 also allows production to begin without waiting for the delayed Conroe facility plan.
Read all positive factors
GeneOne Life Science, Inc. (011000) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩48.51B
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth-64.38%
EPS Growth10.38%
CountryKR
Employees46
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-11847.90
Shares Outstanding18,176,582
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.82
Price to Sales (P/S)1.40
P/FCF Ratio-2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GeneOne Life Science, Inc. Business Overview & Revenue Model
Company Description
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several c...
GeneOne Life Science, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.01B | 23.93B | 35.72B | 40.20B | 48.72B | 38.70B |
| Gross Profit | -14.29B | -21.43B | -10.87B | -7.76B | 9.34B | 8.76B |
| EBITDA | -26.25B | -28.60B | -28.64B | -63.70B | -25.32B | -6.51B |
| Net Income | -41.21B | -47.66B | -48.54B | -77.77B | -38.15B | -15.95B |
Balance Sheet | ||||||
| Total Assets | 131.29B | 119.21B | 151.33B | 151.01B | 222.87B | 249.50B |
| Cash, Cash Equivalents and Short-Term Investments | 6.82B | 3.21B | 1.75B | 9.99B | 45.60B | 107.40B |
| Total Debt | 34.15B | 32.96B | 27.13B | 17.16B | 19.67B | 18.40B |
| Total Liabilities | 80.13B | 78.31B | 65.73B | 39.52B | 41.40B | 44.04B |
| Stockholders Equity | 51.15B | 40.90B | 85.61B | 111.49B | 181.47B | 206.51B |
Cash Flow | ||||||
| Free Cash Flow | -15.91B | -16.55B | -19.42B | -27.40B | -69.52B | -87.37B |
| Operating Cash Flow | -15.88B | -16.52B | -16.06B | -21.74B | -24.11B | -4.85B |
| Investing Cash Flow | -1.97B | -769.89M | -2.85B | 25.89B | 8.06B | -146.40B |
| Financing Cash Flow | 21.97B | 17.45B | 10.96B | -8.29B | 7.01B | 111.02B |
GeneOne Life Science, Inc. Technical Analysis
Negative
―
Price Trends
2670.00
Neutral
2883.35
Negative
4632.30
Negative
Market Momentum
-2.49
Negative
27.53
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:011000, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 2670.00, equal to the 50-day MA of 2670.00, and equal to the 200-day MA of 4632.30, indicating a neutral trend. The MACD of -2.49 indicates Negative momentum. The RSI at 27.53 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:011000.
GeneOne Life Science, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩587.91B | 12.63 | ― | 0.51% | 51.28% | 124.70% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩249.70B | -2.64 | ― | ― | 84.72% | -480.97% | |
43 Neutral | ₩302.45B | -16.97 | ― | ― | 116.74% | -482.50% | |
43 Neutral | ₩2.53T | -30.20 | ― | ― | 23.25% | -58.35% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,680.00
-74.20%
KR:005690
Pharmicell Co., Ltd
9,800.00
-7,391.53
-43.00%
KR:0126Z0
Samsung Epis Holdings Co., Ltd.
307,000.00
-131,500.00
-29.99%
KR:199800
ToolGen Incorporated
30,950.00
-25,409.59
-45.08%
KR:302440
SK bioscience Co.,Ltd.
32,200.00
-18,700.00
-36.74%
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,155.00
-8,525.00
-67.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.